Blackstone Life Sciences
In 2021, Autolus signed a strategic collaboration with Blackstone Life Sciences, where Blackstone committed to invest up to $250 million to develop obe-cel in adult ALL. This collaboration validates the commercial opportunity in adult ALL and funds development and filing of obe-cel in relapsed / refractory adult ALL, as well as funding commercial and manufacturing infrastructure build.
Progress of the obe-cel program triggered $70 million in milestone payments from Blackstone in Q4 2022.
In January 2023 Autolus signed an agreement Cabaletta Bio giving them access to the RQR8 safety switch for selected cell therapy programs for the treatment of autoimmune diseases
Bristol Myers Squibb
In October 2022, Autolus signed an agreement with Bristol Myers Squib giving them access to the RQR8 safety switch for selected cell therapy programs for the treatment of cancer
In 2021, Autolus signed an option and license agreement with Moderna for access to proprietary targeting technology from Autolus. The agreement granted exclusive access to develop and commercialize mRNA therapeutics for up to four immuno-oncology targets.
In Q4 2022, Moderna exercised the option on an undisclosed immune-oncology target.
We have been collaborating with UCL since Autolus was founded. Our strategic collaboration leverages expertise from clinical and translation sciences teams across the two organizations and allows us to rapidly develop programs into the clinic. Our partnership with UCL has been critical to demonstrating the clinical benefits of obe-cel in patients with adult ALL.